La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Praxis Precision Medicine a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Praxis Precision Medicine..

Praxis Precision Medicine (NASDAQ:PRAX) Azioni, Catena delle Opzioni

Praxis Precision Medicine

Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The firm's pipeline covers PRAX-114, for the treatment of a broad range of patients suffering from major depressive disorder and post-traumatic stress disorder; PRAX-944, for the treatment of Essential Tremor and Parkinson's Disease; PRAX-562, and PRAX-222, among others.

Praxis Precision Medicines, Inc. - Common Stock

Praxis Precision Medicines Inc

Praxsyn Corp

TRNR

Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending

VLCN

FCEL

Chardan Capital analyst Daniil Gataulin maintains Ocugen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCGN#NASDAQ">OCGN</a>) with a Buy and maintains $6 price target.

News

Price Target

Analyst Ratings

OCGN

Chardan Capital Maintains Buy on Ocugen, Maintains $6 Price Target

Chardan Capital analyst Matthew Barcus maintains Zura Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZURA#NASDAQ">ZURA</a>) with a Buy and lowers the price target from $14 to $12.

ZURA

Chardan Capital Maintains Buy on Zura Bio, Lowers Price Target to $12

Canaccord Genuity analyst Yuri Lynk upgrades Stantec (TSX:<a class="ticker" href="https://www.benzinga.com/stock/STN#TSX">STN</a>) from Hold to Buy and raises the price target from C$125 to C$135.

Upgrades

TSX:STN

Canaccord Genuity Upgrades Stantec to Buy, Raises Price Target to C$135

Wells Fargo analyst Andrew Bauch maintains Affirm Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFRM#NASDAQ">AFRM</a>) with a Overweight and raises the price target from $52 to $55.

AFRM

Wells Fargo Maintains Overweight on Affirm Holdings, Raises Price Target to $55

Loop Capital analyst Yun Kim maintains Dynatrace (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DT#NYSE">DT</a>) with a Hold and raises the price target from $45 to $55.

Loop Capital Maintains Hold on Dynatrace, Raises Price Target to $55

GameStop Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GME#NYSE">GME</a>), SoFi Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOFI#NASDAQ">SOFI</a>), Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>), Cassava Sciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAVA#NASDAQ">SAVA</a>) and Anavex Life Sciences Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVXL#NASDAQ">AVXL</a>) are the top five trending tickers on Stocktwits Friday. Here&#8217;s a look at what grabbed <a href="https://www.benzinga.com/trading-ideas/24/11/41856335/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet-42">retail investors&#8217; attention.</a>
GME GM-Meme: GameStop tops the list this week. The stock moved on heavy volume and zero fundamentals Friday, as the original meme-stock tends to do. Keith Gill, a.k.a. Roaring Kitty, dumped his Chewy, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHWY#NYSE">CHWY</a>) shares at the <a href="https://www.benzinga.com/news/24/10/41614177/roaring-kitty-puts-chewy-stock-in-the-litter-box-gamestop-shares-move-higher-after-hours">end of October </a>and GameStop has climbed steadily since.&nbsp;
SOFI Surges: SoFi shares have climbed 17%<a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/41847971/jim-cramer-this-tech-stock-is-a-buy-sofi-technologies-is-good"> this week</a> as investors hope for deregulation under a second Trump presidency. The stock pumped on heavy volume and ended the day more than 9% higher. 
Read Next: <a href="https://www.benzinga.com/news/24/11/41781921/what-does-trumps-victory-mean-for-ev-giant-tesla-and-the-big-3-automakers">What Does Trump&#8217;s Victory Mean For EV Giant Tesla And The Big 3 Automakers?</a>
TSLA For President: Tesla shares blasted higher after Donald Trump won the presidential election. Tesla CEO Elon Musk joined Trump several times on the campaign trail and may even be appointed to a position in the administration.&nbsp;
Investors may also consider Trump's EV and tariff policy beneficial to Tesla, as both could potentially reduce competition for the U.S.-based EV giant. The stock has been up 30% since Tuesday, and its market cap has <a href="https://www.benzinga.com/news/management/24/11/41856784/elon-musks-wealth-tops-300-billion-as-teslas-market-cap-soars-above-1-trillion">now reached </a>more than $1 trillion. 
SAVA: Cassava Sciences is a frequent flier on the Stocktwits trending list. HC Wainwright &amp; Co. analyst Vernon Bernardino reiterated Cassava Sciences as a Buy and maintained an ambitious price target of $116 on Friday. The stock is currently trading at just under $27. 
AVXL: Anavex Life Sciences rounds out the list as another heavily-shorted biotech stock that moved on heavy volume, despite a lack of news. According to data from Benzinga Pro, 21.78% of shares are being sold short, and the stock saw more than triple its average trading volume on Friday. 
GME, SOFI, TSLA, SAVA, AVXL Price Action: According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, GameStop shares closed up 6.1% at $24.88, SoFi shares closed up 9.33% at $13.01, Tesla shares closed up 8.19% at $321.22, Cassava Sciences shares closed up 6.55% at $27.00 and Anavex Life Sciences shares ended the day up 21% at $9.24 on Friday.&nbsp;
Read More:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/11/41822473/trumps-potential-health-czar-robert-f-kennedy-jr-rattles-vaccine-stocks-shoot-first-reaction">Trump&#8217;s Potential &#8216;Health Czar&#8217; Robert F. Kennedy Jr. Rattles Vaccine Stocks: &#8216;Shoot First Reaction&#8217;</a></li>
</ul>
Image: Shutterstock

Biotech

Large Cap

Topics

Movers

General

AVXL

CHWY

SAVA

SOFI

TSLA

Friday's Top 5 Trending Stocks: What's The Scoop On GameStop, SoFi, Tesla?

Loop Capital analyst Alton Stump upgrades Domino's Pizza (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DPZ#NYSE">DPZ</a>) from Hold to Buy and raises the price target from $419 to $559.

Loop Capital Upgrades Domino's Pizza to Buy, Raises Price Target to $559

Jones Trading analyst Jason Weaver maintains GEO Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GEO#NYSE">GEO</a>) with a Buy and raises the price target from $18.75 to $32.

Jones Trading Maintains Buy on GEO Group, Raises Price Target to $32

EF Hutton analyst Jason Kolbert maintains CytoSorbents (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTSO#NASDAQ">CTSO</a>) with a Buy and maintains $10 price target.

CTSO

EF Hutton Maintains Buy on CytoSorbents, Maintains $10 Price Target

Telsey Advisory Group analyst Dana Telsey maintains Warby Parker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WRBY#NYSE">WRBY</a>) with a Outperform and raises the price target from $19 to $22.

WRBY

Telsey Advisory Group Maintains Outperform on Warby Parker, Raises Price Target to $22

Rosenblatt analyst Kevin Cassidy maintains Ouster (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OUST#NYSE">OUST</a>) with a Buy and maintains $17 price target.

OUST

Rosenblatt Maintains Buy on Ouster, Maintains $17 Price Target

Rosenblatt analyst Catharine Trebnick maintains RingCentral (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RNG#NYSE">RNG</a>) with a Buy and maintains $45 price target.

Rosenblatt Maintains Buy on RingCentral, Maintains $45 Price Target

Rosenblatt analyst Catharine Trebnick maintains Fortinet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTNT#NASDAQ">FTNT</a>) with a Buy and raises the price target from $85 to $90.

FTNT

Rosenblatt Maintains Buy on Fortinet, Raises Price Target to $90

Planet 13 Holdings Inc. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/PLNH#OTC">PLNH</a>) reported Friday afternoon a strong revenue increase of 29.7% year-over-year for Q3 2024, reaching $32.2 million. The growth was fueled by the expansion into the Florida market and solid performance at its Illinois store. 
Despite the revenue boost, the company posted a net loss of $7.4 million; still a significant improvement from the $46.3 million net loss in Q3 2023.
<ul>
<li>Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter&nbsp;<a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. You can&#8217;t afford to miss out if you're serious about the business.</li>
</ul>
<h3 class="wp-block-heading">Improved Margins&nbsp;</h3>
The company's gross profit rose to $16.7 million, up from $11.1 million in the same quarter last year. Gross margins also improved, reaching 51.9%, compared to 44.7% previously. Planet 13 attributed the margin growth to enhanced yields from cultivation and higher margin sales in <a href="https://www.benzinga.com/topic/florida-cannabis">Florida</a>.&nbsp;
Operating expenses dropped sharply by 66.4%, thanks to reduced impairment losses, signaling better cost management.
Read Also:<a href="https://www.benzinga.com/general/health-care/24/11/41843261/kentucky-gov-beshear-the-jury-is-no-longer-out-kentuckians-want-medical-cannabis"> Kentucky Gov. Beshear: &#8216;The Jury Is No Longer Out,&#8217; Kentuckians Want Medical Cannabis</a>
<h3 class="wp-block-heading">Adjusted EBITDA And Future Outlook</h3>
Planet 13 reported an adjusted EBITDA of $1.3 million, a substantial increase from $0.2 million in Q3 2023, highlighting improved operating leverage.&nbsp;
In spite of consumer spending challenges, co-CEO Bob Groesbeck<a href="https://www.globenewswire.com/us/news-release/2024/11/08/2977890/0/en/Planet-13-Announces-Q3-2024-Financial-Results.html"> pointed out </a>the strategic focus on cash flow and scaling its footprint.
"Despite Florida not moving forward with adult-use [cannabis legalization], we see a significant growth runway by expanding our store footprint and enhancing cultivation assets in the state. In addition to our<a href="https://www.benzinga.com/topic/florida-cannabis"> Florida operations</a>, we&#8217;re focused on driving growth by scaling our neighborhood store network and broadening the distribution of our HaHa edibles," said Larry Scheffler, co-CEO of Planet 13.
With $27.4 million in cash, up from $11.8 million at the end of 2023, Planet 13 is positioning itself for future growth. The company's expansion in Florida and recent acquisitions signal a commitment to broadening its market presence as it aims for profitability in 2025.
Read Next: <a href="https://www.benzinga.com/news/earnings/24/11/41843751/canopy-growth-q2-net-revenue-drops-9-yoy-projects-positive-earnings-ahead">Canopy Growth: Q2 Net Revenue Drops 9% YoY, Projects Positive Earnings Ahead</a>

Cannabis

Earnings

Management

Markets

PLNH

Planet 13 Slashes Costs 66%: Revenue Grows, Losses Shrink — Is This The Turning Point?

Rosenblatt analyst Catharine Trebnick maintains Five9 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FIVN#NASDAQ">FIVN</a>) with a Buy and raises the price target from $45 to $50.

FIVN

Rosenblatt Maintains Buy on Five9, Raises Price Target to $50

Rosenblatt analyst Barton Crockett maintains Pinterest (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PINS#NYSE">PINS</a>) with a Buy and lowers the price target from $48 to $46.

PINS

Rosenblatt Maintains Buy on Pinterest, Lowers Price Target to $46

Rosenblatt analyst Barton Crockett maintains Liberty Formula One Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FWONK#NASDAQ">FWONK</a>) with a Buy and raises the price target from $91 to $93.

FWONK

Rosenblatt Maintains Buy on Liberty Formula One Gr, Raises Price Target to $93

Praxis Precision Medicines: Great Price Movement, But Still Not Convinced

Praxis Precision Medicines ( ($PRAX) ) has shared an announcement. Praxis Precision Medicines has updated its executive employment agreements, part...

Praxis Precision Updates Executive Severance Packages

Meetings to be held October 29-30 hosted by Oppenheimer. Published first on TheFly – the ultimate source for real-time, market-moving breaking fina...

Praxis Precision management to meet with Oppenheimer

Praxis Precision Medicines GAAP EPS of -$2.75 misses by $0.76, revenue of $0.3M in-line

Praxis Precision Medicines ( ($PRAX) ) has shared an announcement. Praxis Precision Medicines is advancing its CNS disorder therapies, with promisi...

Praxis Precision Advances CNS Disorder Therapies

Needham analyst Ami Fadia maintained a Buy rating on Praxis Precision Medicines (PRAX – Research Report) today and set a price target of $151.00. A...

Optimistic Buy Rating for Praxis Precision Medicines Amid Strategic Pipeline Advancements and Long-term Growth Potential

09:38 EST Praxis Precision (PRAX) Medicines trading resumes Published first on TheFly – the ultimate source for real-time, market-moving breaking f...

Praxis Precision Medicines trading resumes

Praxis Precision Medicines, Inc. ( ($PRAX) ) has released its Q3 earnings. Here is a breakdown of the information Praxis Precision Medicines, Inc. ...

Praxis Precision Medicines Reports Q3 2024 Results and Progress

H.C. Wainwright analyst Douglas Tsao has reiterated their bullish stance on PRAX stock, giving a Buy rating yesterday. Douglas Tsao's rating is bas...

Optimistic Growth Outlook for Praxis Precision Medicines Amid Strategic Developments in Ulixacaltamide and Energy Program

In a report released yesterday, Joel Beatty from Robert W. Baird maintained a Buy rating on Praxis Precision Medicines (PRAX – Research Report), wi...

Praxis Precision Medicines: Strong Buy Rating Amid Potential Upside and Robust Pipeline Despite Operational Challenges

PRAX

Press Releases

Praxis Precision Medicines to Announce Second Quarter 2024 Financial Results and Host Conference Call on Tuesday, August 13, 2024

Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2024 Financial Results

Health Care

Praxis Precision Medicines to Announce Topline Data from the Phase 2 EMBOLD Study of Relutrigine (PRAX-562) in SCN2A and SCN8A Developmental and Epileptic Encephalopathies on September 3, 2024

Praxis Precision Medicines announces positive topline results from the EMBOLD study in SCN2A and 8A developmental epilepsies, highlighting the disease-modifying potential of relutrigine

Praxis Precision Medicines to highlight their Epilepsy Portfolio at the International League Against Epilepsy 15th European Epilepsy Congress with six presentations

Comments

Praxis Precision Medicine

Praxis Precision Medicine (PRAX) Opzioni

Praxis Precision Medicine (NASDAQ:PRAX) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO